Peer-Reviewed Journal Details
Mandatory Fields
Carroll, J;Draper, LA;O'Connor, PM;Coffey, A;Hill, C;Ross, RP;Cotter, PD;O'Mahony, J
2010
August
International Journal of Antimicrobial Agents
Comparison of the activities of the lantibiotics nisin and lacticin 3147 against clinically significant mycobacteria
Validated
WOS: 62 ()
Optional Fields
RESISTANT STAPHYLOCOCCUS-AUREUS GRAM-POSITIVE PATHOGENS PRECURSOR LIPID-II ANTIMICROBIAL PEPTIDES BACTERIOCINS ANTIBIOTICS FOOD SUSCEPTIBILITY BIOSYNTHESIS GENERATION
36
132
136
The aim of this study was to use the microtitre alamarBlue assay to investigate and compare the antimycobacterial potential of the lantibiotics nisin and lacticin 3147 against a representative cohort of clinically significant mycobacteria, i.e. Mycobacterium tuberculosis H37Ra, Mycobacterium avium subsp. paratuberculosis (MAP) ATCC 19698 and Mycobacterium kansasii CIT11/06. Lacticin 3147 displayed potent activity against all strains of mycobacteria, with MIC(90) values (lowest concentration of lantibiotic that prevented growth of >90% of the bacterial population) of 60 mg/L and 15 mg/L for M. kansasii and MAP, respectively. Lacticin 3147 was particularly effective against M. tuberculosis H37Ra, with a MIC(90) value of 7.5 mg/L. Nisin, although inhibitory, was generally less potent against all strains of mycobacteria, with MIC(90) values of 60 mg/L for M. kansasii and >60 mg/L for MAP and M. tuberculosis H37Ra. Thus, lacticin 3147 is a potent antimycobacterial peptide that shows superior activity compared with nisin at physiological pH. (C) 2010 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
AMSTERDAM
0924-8579
10.1016/j.ijantimicag.2010.03.029
Grant Details